Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy

Table 5 Summary of ongoing heart failure outcome trials of sodium-glucose cotransporter 2 inhibitors

	PRESERVED-HF	DELIVER	DAPA ACT HF-TIMI 68	EMPEROR-Preserved	EMPULSE
NCT number	03030235	03619213	04363697	03057951	04157751
Population	HFpEF with or without T2DM	HFpEF with or without T2DM	Acute heart failure with reduced ejection fraction	HFpEF with or without T2DM	Acute Heart Failure
Sample size	320	4700	2400	5750	500
Intervention	Dapagliflozin/placebo	Dapagliflozin/placebo	Dapagliflozin/placebo	Empagliflozin/placebo	Empagliflozin/placebo
Primary endpoint	Change from baseline in NT-proBNP	Time-to-first occurrence of CV death, HF hospitalization, or urgent HF visit	CV death or worsening HF	Time-to-first event of HF hospitalization	Death, number of HF events
Status	Estimated completion; February 2021	Estimated completion; June 2021	Estimated completion; October 2022	Estimated completion; April 2021	Estimated completion; June 2021

HFpEF: Heart failure with preserved ejection fraction; T2DM: Type 2 diabetes mellitus; CV: Cardiovascular; HF: Heart failure; NT-proBNP: N-terminal pro-brain natriuretic peptide.